Live Earnings Conference Call: Capricor Therapeutics will host a live Q2 2026 earnings call on August 13, 2026 at 4:30PM ET. NASDAQ:CAPR Capricor Therapeutics Q2 2026 Earnings Report $4.34 +0.15 (+3.46%) As of 02:28 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallCapricor Therapeutics Q2 202600:00 / 00:00Live Transcript Follow Audio Capricor Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.59Beat/MissN/AOne Year Ago EPSN/ACapricor Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.08 millionBeat/MissN/AYoY Revenue GrowthN/ACapricor Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Capricor Therapeutics Earnings HeadlinesCAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 20261 hour ago | prnewswire.comCAPR INVESTOR NOTICE: RGRD Law Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit2 hours ago | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 13 at 1:00 AM | Chaikin Analytics (Ad)INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR4 hours ago | prnewswire.comCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawAugust 13 at 5:04 AM | prnewswire.comCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRAugust 13 at 4:12 AM | prnewswire.comSee More Capricor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email. Email Address About Capricor TherapeuticsCapricor Therapeutics (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms. The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Capricor has completed a Phase II trial in DMD that demonstrated potential functional benefits in ambulatory and non-ambulatory patients, and it has initiated follow-on studies to further characterize safety and efficacy. In addition, Capricor’s CAP-2003 program harnesses exosomes derived from CDCs to deliver bioactive molecules that may promote tissue repair, representing a next-generation approach to regenerative medicine. Capricor serves patients throughout the United States and collaborates with academic and clinical research institutions to accelerate the translation of its therapies. The company’s research and development efforts are supported by strategic partnerships that provide access to specialized manufacturing, preclinical models, and clinical trial networks. Capricor’s leadership team is led by President and CEO Linda L. Marbán, PhD, who co-founded the company and has overseen its growth from an early-stage venture to a publicly traded biotech enterprise.View Capricor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX’s First Earnings Report Only Made Wall Street More DividedFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit TestRoku's Ad Business Is Growing—These 3 Stocks Could Be NextAxos Financial Keeps Proving the Digital Banking Model Works Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
